中井 正人

中井 正人

助教/外来医長

学歴

1999年3月
北海道旭川東高等学校卒業
2005年3月
北海道大学医学部医学科卒業
2014年9月
北海道大学大学院医学研究科医学専攻博士課程修了

職経

2005年4月
市立札幌病院 初期研修医
2007年4月
市立函館病院消化器内科 医員
2009年4月
JA北海道厚生連網走厚生病院内科・消化器科 医員
2010年4月
北海道大学病院消化器内科 医員
2015年4月
北海道大学病院消化器内科 特任助教
2016年4月
北海道大学病院消化器内科 助教

専門分野

肝臓病学、肝炎ウイルス学、肝腫瘍治療(特にラジオ波焼灼療法)

所属学会

  • 日本内科学会 認定内科医、総合内科専門医
  • 日本消化器病学会 専門医
  • 日本消化器内視鏡学会 専門医
  • 日本肝臓学会 専門医、東部会評議員
  • 日本ウイルス学会

趣味

マラソン、スキー

業績(英文のみ)

  1. Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M, Terashita K, Sakuhara Y, Abo D, Tsukuda Y, Tsunematsu S, Hige S, Kato M,Shirato H, Asaka M.
    Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
    J Gastroenterol Hepatol. 26(7), 1123-32, 2011.
  2. Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M.:Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.
    J Gastroenterol. 47(11),1228-37, 2012.
  3. Nakai M, Seya T, Matsumoto M, Shimotohno K, Sakamoto N, Aly HH.
    The J6JFH1strain of hepatitis C virus infects human B-cells with low replication efficacy. Viral Immunol.27(6),285-94, 2014.
  4. Suda G, Yamamoto Y,Nagasaka A, Furuya K, Kudo M, Chuganji Y, Tsukuda Y, Tsunematsu S, Sato F,Terasita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Fujita Y, Abe R,Taniguchi M, Nakagawa M, Asahina Y, Sakamoto N; NORTE Study Group.
    Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.
    Hepatol Res. 45(8),837-45, 2015.
  5. Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Abdom Imaging. 40(6):1492-9,2015.
  6. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N.
    A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Cancer Biol Ther. 16(10):1453-61,2015.
  7. Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Hepatol Res. 2016 Feb 20. doi: 10.1111/hepr.12685. [Epub ahead of print]
  8. Nakai M, Oshiumi H, Funami K, Okamoto M, Matsumoto M, Seya T, Sakamoto N.
    Interferon (IFN) and cellular immune response evoked in RNA-pattern sensing during infection with Hepatitis C virus (HCV).
    Sensors (Basel). 23;15(10):27160-73,2015
  9. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
    Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016 Jan 14. [Epub ahead of print]
  10. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Takaaki I, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N.
    Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Hepatol Res. 2016 Jul 16. doi: 10.1111/hepr.12775. [Epub ahead of print]
  11. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.
    Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2017 Feb;89(2):267-275.
  12. Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N.
    Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    J Clin Transl Hepatol. 2016 Dec 28;4(4):320-327.
  13. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group.
    Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    J Gastroenterol. 2017 Mar 18. doi: 10.1007/s00535-017-1328-z. [Epub ahead of print]
  14. Tsukuda Y, Suda G, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto N.
    Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection.
    J Med Virol. 2017 May;89(5):857-866.